Cargando…
Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery
PURPOSE: Hypofractionated stereotactic radiosurgery (HF-SRS) with or without surgical resection is potentially a preferred treatment for larger or symptomatic brain metastases (BMs). Herein, we report clinical outcomes and predictive factors following HF-SRS. METHODS AND MATERIALS: Patients undergoi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943776/ https://www.ncbi.nlm.nih.gov/pubmed/36845614 http://dx.doi.org/10.1016/j.adro.2022.101166 |
_version_ | 1784891779367043072 |
---|---|
author | Carpenter, David J. Fairchild, Andrew T. Adamson, Justus D. Fecci, Peter E. Sampson, John H. Herndon, James E. Torok, Jordan A. Mullikin, Trey C. Kim, Grace J. Reitman, Zachary J. Kirkpatrick, John P. Floyd, Scott R. |
author_facet | Carpenter, David J. Fairchild, Andrew T. Adamson, Justus D. Fecci, Peter E. Sampson, John H. Herndon, James E. Torok, Jordan A. Mullikin, Trey C. Kim, Grace J. Reitman, Zachary J. Kirkpatrick, John P. Floyd, Scott R. |
author_sort | Carpenter, David J. |
collection | PubMed |
description | PURPOSE: Hypofractionated stereotactic radiosurgery (HF-SRS) with or without surgical resection is potentially a preferred treatment for larger or symptomatic brain metastases (BMs). Herein, we report clinical outcomes and predictive factors following HF-SRS. METHODS AND MATERIALS: Patients undergoing HF-SRS for intact (iHF-SRS) or resected (rHF-SRS) BMs from 2008 to 2018 were retrospectively identified. Linear accelerator-based image-guided HF-SRS consisted of 5 fractions at 5, 5.5, or 6 Gy per fraction. Time to local progression (LP), time to distant brain progression (DBP), and overall survival (OS) were calculated. Cox models assessed effect of clinical factors on OS. Fine and Gray's cumulative incidence model for competing events examined effect of factors on LP and DBP. The occurrence of leptomeningeal disease (LMD) was determined. Logistic regression examined predictors of LMD. RESULTS: Among 445 patients, median age was 63.5 years; 87% had Karnofsky performance status ≥70. Fifty-three % of patients underwent surgical resection, and 75% received 5 Gy per fraction. Patients with resected BMs had higher Karnofsky performance status (90-100, 41 vs 30%), less extracranial disease (absent, 25 vs 13%), and fewer BMs (multiple, 32 vs 67%). Median diameter of the dominant BM was 3.0 cm (interquartile range, 1.8-3.6 cm) for intact BMs and 4.6 cm (interquartile range, 3.9-5.5 cm) for resected BMs. Median OS was 5.1 months (95% confidence interval [CI], 4.3-6.0) following iHF-SRS and 12.8 months (95% CI, 10.8-16.2) following rHF-SRS (P < .01). Cumulative LP incidence was 14.5% at 18 months (95% CI, 11.4-18.0%), significantly associated with greater total GTV (hazard ratio, 1.12; 95% CI, 1.05-1.20) following iFR-SRS, and with recurrent versus newly diagnosed BMs across all patients (hazard ratio, 2.28; 95% CI, 1.01-5.15). Cumulative DBP incidence was significantly greater following rHF-SRS than iHF-SRS (P = .01), with respective 24-month rates of 50.0 (95% CI, 43.3-56.3) and 35.7% (95% CI, 29.2-42.2). LMD (57 events total; 33% nodular, 67% diffuse) was observed in 17.1% of rHF-SRS and 8.1% of iHF-SRS cases (odds ratio, 2.46; 95% CI, 1.34-4.53). Any radionecrosis and grade 2+ radionecrosis events were observed in 14 and 8% of cases, respectively. CONCLUSIONS: HF-SRS demonstrated favorable rates of LC and radionecrosis in postoperative and intact settings. Corresponding LMD and RN rates were comparable to those of other studies. |
format | Online Article Text |
id | pubmed-9943776 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-99437762023-02-23 Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery Carpenter, David J. Fairchild, Andrew T. Adamson, Justus D. Fecci, Peter E. Sampson, John H. Herndon, James E. Torok, Jordan A. Mullikin, Trey C. Kim, Grace J. Reitman, Zachary J. Kirkpatrick, John P. Floyd, Scott R. Adv Radiat Oncol Scientific Article PURPOSE: Hypofractionated stereotactic radiosurgery (HF-SRS) with or without surgical resection is potentially a preferred treatment for larger or symptomatic brain metastases (BMs). Herein, we report clinical outcomes and predictive factors following HF-SRS. METHODS AND MATERIALS: Patients undergoing HF-SRS for intact (iHF-SRS) or resected (rHF-SRS) BMs from 2008 to 2018 were retrospectively identified. Linear accelerator-based image-guided HF-SRS consisted of 5 fractions at 5, 5.5, or 6 Gy per fraction. Time to local progression (LP), time to distant brain progression (DBP), and overall survival (OS) were calculated. Cox models assessed effect of clinical factors on OS. Fine and Gray's cumulative incidence model for competing events examined effect of factors on LP and DBP. The occurrence of leptomeningeal disease (LMD) was determined. Logistic regression examined predictors of LMD. RESULTS: Among 445 patients, median age was 63.5 years; 87% had Karnofsky performance status ≥70. Fifty-three % of patients underwent surgical resection, and 75% received 5 Gy per fraction. Patients with resected BMs had higher Karnofsky performance status (90-100, 41 vs 30%), less extracranial disease (absent, 25 vs 13%), and fewer BMs (multiple, 32 vs 67%). Median diameter of the dominant BM was 3.0 cm (interquartile range, 1.8-3.6 cm) for intact BMs and 4.6 cm (interquartile range, 3.9-5.5 cm) for resected BMs. Median OS was 5.1 months (95% confidence interval [CI], 4.3-6.0) following iHF-SRS and 12.8 months (95% CI, 10.8-16.2) following rHF-SRS (P < .01). Cumulative LP incidence was 14.5% at 18 months (95% CI, 11.4-18.0%), significantly associated with greater total GTV (hazard ratio, 1.12; 95% CI, 1.05-1.20) following iFR-SRS, and with recurrent versus newly diagnosed BMs across all patients (hazard ratio, 2.28; 95% CI, 1.01-5.15). Cumulative DBP incidence was significantly greater following rHF-SRS than iHF-SRS (P = .01), with respective 24-month rates of 50.0 (95% CI, 43.3-56.3) and 35.7% (95% CI, 29.2-42.2). LMD (57 events total; 33% nodular, 67% diffuse) was observed in 17.1% of rHF-SRS and 8.1% of iHF-SRS cases (odds ratio, 2.46; 95% CI, 1.34-4.53). Any radionecrosis and grade 2+ radionecrosis events were observed in 14 and 8% of cases, respectively. CONCLUSIONS: HF-SRS demonstrated favorable rates of LC and radionecrosis in postoperative and intact settings. Corresponding LMD and RN rates were comparable to those of other studies. Elsevier 2022-12-29 /pmc/articles/PMC9943776/ /pubmed/36845614 http://dx.doi.org/10.1016/j.adro.2022.101166 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Scientific Article Carpenter, David J. Fairchild, Andrew T. Adamson, Justus D. Fecci, Peter E. Sampson, John H. Herndon, James E. Torok, Jordan A. Mullikin, Trey C. Kim, Grace J. Reitman, Zachary J. Kirkpatrick, John P. Floyd, Scott R. Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery |
title | Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery |
title_full | Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery |
title_fullStr | Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery |
title_full_unstemmed | Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery |
title_short | Outcomes in Patients with Intact and Resected Brain Metastasis Treated with 5-Fraction Stereotactic Radiosurgery |
title_sort | outcomes in patients with intact and resected brain metastasis treated with 5-fraction stereotactic radiosurgery |
topic | Scientific Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943776/ https://www.ncbi.nlm.nih.gov/pubmed/36845614 http://dx.doi.org/10.1016/j.adro.2022.101166 |
work_keys_str_mv | AT carpenterdavidj outcomesinpatientswithintactandresectedbrainmetastasistreatedwith5fractionstereotacticradiosurgery AT fairchildandrewt outcomesinpatientswithintactandresectedbrainmetastasistreatedwith5fractionstereotacticradiosurgery AT adamsonjustusd outcomesinpatientswithintactandresectedbrainmetastasistreatedwith5fractionstereotacticradiosurgery AT feccipetere outcomesinpatientswithintactandresectedbrainmetastasistreatedwith5fractionstereotacticradiosurgery AT sampsonjohnh outcomesinpatientswithintactandresectedbrainmetastasistreatedwith5fractionstereotacticradiosurgery AT herndonjamese outcomesinpatientswithintactandresectedbrainmetastasistreatedwith5fractionstereotacticradiosurgery AT torokjordana outcomesinpatientswithintactandresectedbrainmetastasistreatedwith5fractionstereotacticradiosurgery AT mullikintreyc outcomesinpatientswithintactandresectedbrainmetastasistreatedwith5fractionstereotacticradiosurgery AT kimgracej outcomesinpatientswithintactandresectedbrainmetastasistreatedwith5fractionstereotacticradiosurgery AT reitmanzacharyj outcomesinpatientswithintactandresectedbrainmetastasistreatedwith5fractionstereotacticradiosurgery AT kirkpatrickjohnp outcomesinpatientswithintactandresectedbrainmetastasistreatedwith5fractionstereotacticradiosurgery AT floydscottr outcomesinpatientswithintactandresectedbrainmetastasistreatedwith5fractionstereotacticradiosurgery |